Oliver Josef Müller

The paper evaluates multi-laboratory studies to identify promising treatments by assessing effect sizes and experimental rigor across different medical fields.

This study identifies ceramide-driven lipotoxicity as a driver of calcific aortic valve disease and shows that SPT inhibition can reverse disease progression in vivo.

This study identifies FYCO1 as a regulator of autophagy that improves cardiac remodeling after myocardial infarction by enhancing autophagic flux and reducing inflammation.

This paper identifies immunomodulatory endothelial cells (IMEC) that present antigens on MHC class II and activate T cells in atherosclerosis.

This study identifies nuclear eNOS's role in modulating ADAR1 activity and type I interferon signaling, linking NO bioavailability to endothelial function and atherogenesis.

This study investigates how infection and pesticide exposure lead to α-Synuclein Ser129 phosphorylation through c-Abl kinase activation and identifies potential therapeutic targets.

This study identifies lncRNA Bigheart as a key regulator of calcineurin-NFAT signaling in myocardial hypertrophy, showing its role in driving maladaptive hypertrophy and susceptibility to heart failure.